<DOC>
	<DOCNO>NCT01911065</DOCNO>
	<brief_summary>In study investigator try identify immune signature associate effective poor vaccine responses naturally-acquired herpes zoster virus zoster ( shingle ) vaccine , Zostavax .</brief_summary>
	<brief_title>T Cell Responses Varicella Zoster Virus ( VZV ) Vaccine SLVP020</brief_title>
	<detailed_description>This study examine frequency , phenotype repertoire VZV-specific T cell . The frequency T-Cell Receptor ( TCR ) diversity VZV-specific T cell day 7 14 vaccination examine . The titer anti-VZV antibody T cell frequency examine day 28 post vaccination .</detailed_description>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Chickenpox</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Otherwise healthy adult nontwins twin pair , 4049 year age ( CrossSectional study ) 50 year age old ( Vaccination study ) . If volunteer participate Vaccination study screening , may consider CrossSectional study . History prior chicken pox infection living within continental U.S. past 30 year Willing complete informed consent process Availability followup plan duration study ( CrossSectional study : 1 visit ; Vaccination study : 5 visit within 45 week ) Acceptable medical history vital sign History shingle within 5 year enrollment Prior vaccination Zostavax vaccine prevention shingle Vaccination Study : History severe allergic reaction vaccine component , include gelatin neomycin . Vaccination Study : Lifethreatening reaction previous vaccination . Vaccination Study : Adults weigh less 110 pound . Active systemic serious concurrent illness , include febrile illness day enrollment/vaccination History immunodeficiency disorder Chronic HIV , Hepatitis B Hepatitis C infection Known suspect impairment immunologic function , include , limited clinically significant liver disease , diabetes mellitus treat insulin , moderate severe renal disease chronic disorder , opinion investigator , might jeopardize volunteer safety compliance protocol . Recent current use immunosuppressive medication , anticipate use study period , include systemic corticosteroid ( corticosteroid nasal spray , inhaled steroid topical steroid permissible ) . Blood pressure &gt; 150 systolic &gt; 95 diastolic Visit 1 History chemotherapy treatment cancer . Malignancy , squamous cell basal cell skin cancer ( include solid tumor breast cancer recurrence past year hematologic cancer leukemia lymphoma ) , opinion investigator , might jeopardize volunteer safety compliance protocol . Prostate cancer may acceptable metastasis undergo treatment immunosuppressive medication . Autoimmune disease , include rheumatoid arthritis , treat immunosuppressive medication Plaquenil , methotrexate , prednisone , Enbrel , opinion investigator , might jeopardize volunteer safety compliance protocol ( thyroid disease may acceptable ) . History blood dyscrasia , renal disease , hemoglobinopathies require regular medical follow hospitalization precede year Use anticoagulation medication Coumadin Lovenox , antiplatelet agent aspirin ( except aspirin 325 mg. daily ) , Plavix Aggrenox may , opinion investigator , jeopardize volunteer safety compliance protocol . Receipt blood blood product within 6 month prior enrollment study period Use antiviral medication within 24 hr . prior enrollment , Vaccination study , 14 day follow study vaccination . Inactivated vaccine within 14 day prior enrollment study period ( avoid nonstudy relate immunization study period ) Live , attenuate vaccine within 60 day prior enrollment study period ( avoid nonstudy relate immunization study period ) Pregnant lactate woman , plan become pregnant ( pregnancy avoid 3 month follow administration Zostavax vaccine ) . Use investigational agent within 30 day prior enrollment study period Donation unit blood within 6 week prior enrollment study period Medical psychiatric condition occupational responsibility preclude subject compliance protocol Any condition , opinion investigator , might interfere volunteer safety , study objective ability participant understand comply study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Herpes zoster</keyword>
	<keyword>immune response</keyword>
	<keyword>Zostavax</keyword>
	<keyword>twin</keyword>
	<keyword>non-twins</keyword>
</DOC>